By combining the inhibition of BMP2 signaling network with a MEK1/2 inhibitor, we have established the therapeutic utility of combinatorial treatment that results in increased cell death, decreased migration and invasion of MPNST cells. Here, MAP2K1 is linked to malignant peripheral nerve sheath tumor.